drugset / Trial / NCT02183415
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
Study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 1356 BS during 4 week treatment duration
Timeline
- Start
- 2005-08
- Primary completion
- 2006-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Linagliptin | Small molecule | 2.5 mg | Oral |
| Subject | Linagliptin | Small molecule | 5 mg | Oral |
| Subject | Linagliptin | Small molecule | 10 mg | Oral |